MindMed appoints Brandi Roberts as CFO effective June 2, 2025; inducement awards granted

Definium Therapeutics, Inc.

Roberts previously CFO of Longboard Pharmaceuticals, led IPO and $2.6B Lundbeck acquisition.
Base salary $495,000; eligible for annual cash bonus up to 40% of base salary.
Inducement awards: option for 500,000 shares (4-year vest) and 125,000 PSUs (3-year vest, 0-200% payout).
Roberts replaces Carrie Liao as principal financial and accounting officer effective June 2.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brandi L. Roberts

Chief Financial Officer

DFTX · Definium Therapeutics, Inc.

Effective: 2025-06-02
Filed: May 27, 2025, 7:59 PM ET

had appointed Brandi L. Roberts as Chief Financial Officer, effective as of June 2, 2025 (the “Effective Date”).

Role change

Carrie Liao

principal financial officer and principal accounting officer

DFTX · Definium Therapeutics, Inc.

Effective: 2025-06-02
Successor: Brandi L. Roberts
Filed: May 27, 2025, 7:59 PM ET

Carrie Liao, the Company’s Chief Accounting Officer, will no longer serve as the Company’s principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brandi L. Roberts was appointed as Chief Financial Officer at Definium Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

had appointed Brandi L. Roberts as Chief Financial Officer, effective as of June 2, 2025 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Carrie Liao changed role as principal financial officer and principal accounting officer at Definium Therapeutics, Inc..

Action: will no longer serve as
Role: principal financial officer and principal accounting officer

Exact text from the filing

Carrie Liao, the Company’s Chief Accounting Officer, will no longer serve as the Company’s principal financial officer and principal accounting officer.

View on SEC.gov

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-052719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.